A new method to quickly identify bloodstream infections.
Highly Multiplexed Single Molecule Tethering
['FUNDING_SBIR_2'] · SCANOGEN, INC. · NIH-10909305
This study is testing a new, quick way to find germs in the blood of patients with sepsis, so doctors can start the right treatment faster and help more people get better.
Quick facts
| Phase | ['FUNDING_SBIR_2'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | SCANOGEN, INC. (nih funded) |
| Locations | 1 site (Baltimore, UNITED STATES) |
| Trial ID | NIH-10909305 on ClinicalTrials.gov |
What this research studies
This research focuses on developing a rapid and comprehensive molecular assay that can identify pathogens directly from whole blood samples in patients showing symptoms of sepsis. The innovative approach, known as Single Molecule Tethering (SMOLT), allows for the detection of multiple microbes simultaneously, significantly reducing the time it takes to diagnose bloodstream infections. The assay is designed to work with low concentrations of microbes and aims to cover over 99% of the organisms responsible for these infections. By integrating this assay into an automated system, the goal is to provide timely and effective antimicrobial therapy to patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients exhibiting symptoms of sepsis or suspected bloodstream infections.
Not a fit: Patients with infections not caused by the targeted organisms or those who do not exhibit sepsis symptoms may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to faster diagnosis and treatment of bloodstream infections, potentially saving lives.
How similar studies have performed: Previous research has shown promise in rapid pathogen detection methods, but this approach aims to significantly enhance multiplexing capabilities, making it a novel advancement.
Where this research is happening
Baltimore, UNITED STATES
- SCANOGEN, INC. — Baltimore, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: CELEDON, ALFREDO ANDRES — SCANOGEN, INC.
- Study coordinator: CELEDON, ALFREDO ANDRES
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.